Standardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy.

IF 3 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Global Heart Pub Date : 2023-11-20 eCollection Date: 2023-01-01 DOI:10.5334/gh.1275

Marianna Fontana, Aldostefano Porcari, Philip N Hawkins

引用次数: 0

Abstract

Transthyretin cardiac amyloidosis (ATTR-CA) has been traditionally considered a rare and inexorably fatal condition. ATTR-CA now is an increasingly recognised cause of heart failure and mortality worldwide with effective pharmacological treatments. Advances in non-invasive diagnosis, coupled with the development of effective treatments, have transformed the diagnosis of ATTR-CA, which is now possible without recourse to endomyocardial biopsy in around 70% of cases. Many patients are now diagnosed at an earlier stage. Echocardiography and cardiac magnetic resonance have enabled identification of patients with possible ATTR-CA and more accurate prognostic stratification. Therapies able to slow or halt ATTR-CA progression and increase survival are now available and there is also evidence that patients may benefit from specific conventional heart failure medications. A wide horizon of possibilities is unfolding and awaits discovery.

查看原文本刊更多论文

转甲状腺素淀粉样蛋白心肌病的规范化护理和治疗。

转甲状腺素型心脏淀粉样变性(atr - ca)历来被认为是一种罕见且致命的疾病。atr - ca现在是世界范围内公认的心衰和死亡原因，并有有效的药物治疗。非侵入性诊断的进步，加上有效治疗方法的发展，已经改变了atr - ca的诊断，现在在大约70%的病例中，无需求助于心内膜肌活检就可以进行诊断。现在许多患者在早期阶段就被诊断出来。超声心动图和心脏磁共振能够识别可能的atr - ca患者，并更准确地进行预后分层。目前已有能够减缓或阻止atr - ca进展并提高生存率的治疗方法，也有证据表明，患者可能受益于特定的常规心力衰竭药物。广阔的前景正在展现，等待着我们去发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Global Heart Medicine-Cardiology and Cardiovascular Medicine

CiteScore

5.70

自引率

5.40%

发文量

审稿时长

5 weeks

期刊介绍： Global Heart offers a forum for dialogue and education on research, developments, trends, solutions and public health programs related to the prevention and control of cardiovascular diseases (CVDs) worldwide, with a special focus on low- and middle-income countries (LMICs). Manuscripts should address not only the extent or epidemiology of the problem, but also describe interventions to effectively control and prevent CVDs and the underlying factors. The emphasis should be on approaches applicable in settings with limited resources. Economic evaluations of successful interventions are particularly welcome. We will also consider negative findings if important. While reports of hospital or clinic-based treatments are not excluded, particularly if they have broad implications for cost-effective disease control or prevention, we give priority to papers addressing community-based activities. We encourage submissions on cardiovascular surveillance and health policies, professional education, ethical issues and technological innovations related to prevention. Global Heart is particularly interested in publishing data from updated national or regional demographic health surveys, World Health Organization or Global Burden of Disease data, large clinical disease databases or registries. Systematic reviews or meta-analyses on globally relevant topics are welcome. We will also consider clinical research that has special relevance to LMICs, e.g. using validated instruments to assess health-related quality-of-life in patients from LMICs, innovative diagnostic-therapeutic applications, real-world effectiveness clinical trials, research methods (innovative methodologic papers, with emphasis on low-cost research methods or novel application of methods in low resource settings), and papers pertaining to cardiovascular health promotion and policy (quantitative evaluation of health programs.